Krystal Biotech, Inc. (FRA:4KB)

Market Cap	6.82B +66.5%
Revenue (ttm)	318.05M +54.5%
Net Income	169.53M +279.8%
EPS	5.68 +275.7%
Shares Out	n/a
PE Ratio	40.20
Forward PE	33.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111
Average Volume	14
Open	245.20
Previous Close	243.80
Day's Range	245.20 - 245.20
52-Week Range	108.40 - 249.50
Beta	n/a
RSI	58.85
Earnings Date	Feb 13, 2026

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 cl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 275
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4KB

Financial Performance

In 2024, Krystal Biotech's revenue was $290.52 million, an increase of 473.02% compared to the previous year's $50.70 million. Earnings were $89.16 million, an increase of 715.58%.

Financial numbers in USD